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Oxidative stress, a central mediator of cardiovascular disease, results in loss of the prosthetic
haem group of soluble guanylate cyclase (sGC), preventing its activation by nitric oxide (NO).
Here we introduce Apo-sGC mice expressing haem-free sGC. Apo-sGC mice are viable and
develop hypertension. The haemodynamic effects of NO are abolished, but those of the sGC
activator cinaciguat are enhanced in apo-sGC mice, suggesting that the effects of NO on
smooth muscle relaxation, blood pressure regulation and inhibition of platelet aggregation
require sGC activation by NO. Tumour necrosis factor (TNF)-induced hypotension and
mortality are preserved in apo-sGC mice, indicating that pathways other than sGC signalling
mediate the cardiovascular collapse in shock. Apo-sGC mice allow for differentiation
between sGC-dependent and -independent NO effects and between haem-dependent and
-independent sGC effects. Apo-sGC mice represent a unique experimental platform to study
the in vivo consequences of sGC oxidation and the therapeutic potential of sGC activators.
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O
xidative stress is a risk factor for cardiovascular
disorders1,2. Oxidative stress interferes with the nitric
oxide (NO)/soluble guanylate cyclase (sGC)/30,50-cyclic
guanosine monophosphate (cGMP) pathway1–3, critical for
cardiovascular and platelet function. First, reactive oxygen
species can uncouple nitric oxide synthase (NOS), resulting in
the production of superoxide (O2-) instead of NO. Second, O2-
scavenges NO, decreasing its bioavailability. Third, oxidative
stress impairs the sensitivity of sGC for NO4. sGC is a
heterodimeric haemoprotein, consisting of an a1 or a2 subunit
combined with a common b1 subunit, which generates cGMP.
Basal catalytic activity of sGC is greatly enhanced upon binding of
NO to the ferrous haem, disrupting the bond between the haem
and the HIS105 residue of sGCb1 (ref. 5). Although sGC is
considered as the principal target of NO, this paradigm has been
challenged by the discovery of signalling pathways involving
protein nitr(osyl)ation6. Oxidation of the ferrous haem,
associated with haem-dissociation in vitro, results in the
generation of haem-free sGC (apo-sGC), which has preserved
basal activity but can no longer be activated by NO7,8. In vitro,
apo-sGC has been shown to be susceptible to ubiquitination and
subsequent proteasomal breakdown9. Levels of apo-sGC are
hypothesized to be increased in conditions of oxidative stress
in vivo4,10–12.
The development of drugs targeting apo-sGC represents a unique
approach to treat pathologies characterized by oxidative stress and
associated with impaired cGMP signalling. Two classes of drugs
modulating sGC activity exist: NO-independent, haem-dependent
sGC stimulators, such as BAY 41-2272 and riociguat (Adempas or
BAY 63-2521)13, and NO- and haem-independent sGC activators,
such as cinaciguat (BAY 58-2667) and ataciguat (HMR1766)14,15.
The therapeutic potential of riociguat was recently illustrated in
phase III clinical trials for the treatment of pulmonary arterial
hypertension (PAH)13 and subsequent Food and Drug
Administration approval for PAH treatment. However, the
inability to distinguish native, haem-containing sGC from
oxidized/haem-free sGC8 in vivo has precluded investigations into
the speciﬁc pathological consequences of impaired sGC activity
through haem-oxidation in vivo, as well as the consequences of
speciﬁcally activating the oxidized/haem-free pool of sGC in vivo.
To provide a scientiﬁc basis for the concept of targeting apo-sGC as
a pharmacological strategy, we generated mice expressing haem-free
sGC (apo-sGC mice) instead of native sGC, by mutation of the
HIS105 residue of sGCb1 to PHE105.
Here, we report the in vivo cardiovascular phenotype of
apo-sGC mice, identifying activation of haem-containing reduced
sGC as the essential mechanism by which NO induces
vasorelaxation, lowers blood pressure (BP) and inhibits platelet
aggregation. Our data suggest that sGC activators, a new class of
drugs in development for the treatment of a variety of
cardiovascular diseases, can attenuate haemodynamic abnormal-
ities associated with oxidative stress. In addition, apo-sGC mice
allow to distinguish between sGC-dependent effects and sGC-
independent effects of NO, such as nitr(osyl)ation, and to
discriminate between haem-dependent and haem-independent
effects of sGC. For example, the role of NO-sGC signalling in the
potentially lethal cardiovascular collapse associated with over-
whelming systemic inﬂammation is controversial. Septic or
inﬂammatory shock remains the primary cause of death in
intensive care units16 and NO signalling is considered a central
pathway of the cardiovascular collapse associated with the
resulting systemic shock. The prevailing paradigm identiﬁes
sGC as a central mediator leading to hypotension, shock and
mortality in systemic inﬂammation17,18. To test this paradigm, we
measured BP, HR and mortality in TNF-induced systemic shock
in apo-sGC and wild-type (WT) mice. Our ﬁndings that apo-sGC
mice are not protected from the cardiovascular collapse and
lethality associated with TNF-induced systemic shock, indicate
that sGC is not a central mediator of hypotension, shock and
mortality in systemic shock.
Results
Generation of apo-sGC mice. Apo-sGC mice were generated
using standard transgenic methods using a targeting strategy
designed so that the WT exon 5 of the endogenous Gucy1b3 gene
was replaced with a mutant exon 5 carrying the H105F point
mutation, resulting in replacement of the WT histidine, which is
responsible for ligation of the haem-group to sGC19, with a
phenylalanine (Supplementary Fig. 1a.). Analysis of progeny
showed that mice heterozygous (HE) and homozygous knock-in
(KI) for the knock-in mutation were viable but with a skewed
Mendelian segregation in the offspring of HE breeders at 21 days
of life (27% WT (n¼ 1,172), 51% HE (n¼ 2,252), 22% apo-sGC
(n¼ 987); w2¼ 17.5; Po0.001).
Molecular characterization of apo-sGC mice. mRNA expression
levels of transcripts for sGCa1, sGCa2 and sGCb1 protein were
similar in the brain, the kidney, the lung and the left ventricle of
apo-sGC (KI), HE, and WT mice (Fig. 1a), indicating that intro-
duction of the H105F mutation in sGCb1 does not affect expression
of sGC subunits. Similarly, no changes were observed in the
expression of genes encoding other relevant proteins in the NO/
cGMP signalling pathway (Supplementary Fig. 2). In contrast to the
similar gene expression levels in the different genotypes, sGCa1,
sGCa2 and sGCb1 protein levels were lower in tissues of apo-sGC
and HE mice than in WT mice (Fig. 1b and Supplementary Fig. 3).
Basal cGMP levels in tissues did not differ between apo-sGC, HE
and WT mice (Fig. 1c). Baseline sGC activity was similar in lung
and aorta homogenates of apo-sGC and WT mice (Fig. 1d,e). The
ability of the NO-donor compound diethylenetriamine NO
(DETA-NO) to increase cGMP levels in vivo was attenuated and
absent in aortas of HE or apo-sGC mice, respectively (Fig. 1c).
Similarly, DETA-NO was unable to increase sGC activity in tissue
extracts from the lung and the aorta of apo-sGC mice (Fig. 1d,e). In
contrast, cinaciguat, a haem-independent sGC activator, activated
sGC in apo-sGC tissue extracts (Fig. 1d,e).
Apo-sGC enzyme function in CHO cells. The combined
observation of reduced sGC protein levels together with preserved
basal cGMP levels suggests that the apo-sGC enzyme has a higher
basal activity than the WT enzyme. To test this hypothesis, we
assessed apo-sGC enzyme function in vitro in a cGMP reporter
cell line. Basal cGMP production was higher in reporter cells
expressing haem-free sGCb1H105F than in cells expressing
WT-sGC (Fig. 2a).
In reporter cells expressing WT, haem-containing sGC, cGMP
production was increased in a concentration-dependent manner
by cinaciguat (Fig. 2b). Adding the selective sGC inhibitor
1H-[1,2,4] oxadiazolo [4,3-a] quinoxalin-1-one (ODQ), which
exerts its activity through oxidation of the haem, enhanced the
ability of cinaciguat to activate sGC (Fig. 2b). Stimulation with
BAY 41-2272 increased cGMP synthesis in a concentration-
dependent manner (Fig. 2c). Combination of BAY 41-2272 with
1 nmol l 1 diethylamine NONOate (DEA/NO) synergistically
stimulated sGC (Fig. 2c).
In reporter cells expressing apo-sGC, cinaciguat increased the
activity of apo-sGC (Fig. 2d) in a dose-dependent manner.
Addition of 10mM ODQ did not enhance cinaciguat-induced
sGC activity (Fig. 2d). In contrast, neither BAY 41-2272 alone at
concentrations previously demonstrated to speciﬁcally activate
sGC but not inhibit phosphodiesterase (PDE) activity nor BAY
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41-2272 in combination with NO was able to activate apo-sGC
(Fig. 2e). These data indicate that the activity of apo-sGC is
higher than WT sGC at baseline and that apo-sGC can
concentration dependently be activated by haem-independent
sGC activators but not by haem-dependent sGC stimulators.
Impaired NO-mediated platelet inhibition in apo-sGC mice.
Tail bleeding time, an in vivo measure of platelet reactivity, was
shorter in apo-sGC mice than in WT littermates (Fig. 3a). In
addition, platelet activation studies were performed on isolated
platelets of WT and apo-sGC mice by measuring the ability of an
NO donor compound (sodium nitroprusside (SNP)) to modulate
thrombin-induced surface expression of CD62P. Although
stimulation of platelets with thrombin resulted in a similar
upregulation of CD62P on WT and apo-sGC platelets, SNP
inhibited CD62P expression on WT but not apo-sGC platelets
(Fig. 3b). Together, these data demonstrate that inhibition of
platelet activation is impaired in apo-sGC mice, suggesting that
the ability of NO to inhibit platelet activation critically depends on
sGC.
Haemodynamic response to NO is absent in apo-sGC mice.
We next investigated the in vivo impact of oxidized sGC on
cardiovascular function by measuring BP and heart rate (HR) in
freely moving conscious WT and apo-sGC mice by telemetry,
and in restrained mice by tail-cuff. Systolic BP (SBP) was higher
in conscious apo-sGC mice than in WT mice (Fig. 3c,d,f). HR did
not differ between apo-sGC and WT mice (Fig. 3e,f). Adminis-
tration of the NOS inhibitor No-nitro-L-arginine methyl ester
(L-NAME) in vivo increased BP and decreased HR in WT but not
in apo-sGC mice (Fig. 4a, Supplementary Fig. 4a, 5a,b and
Supplementary Table 3). Similarly, in vivo administration of the
exogenous NO donors DETA-NO, an NO-donor with a half-life
of 20 h at 37 C, and SNP, an NO-donor with a half-life of
o2min at 37 C, decreased BP and increased HR in WT but not
in apo-sGC mice (Fig. 4b,c, Supplementary Fig. 4b,c, 5c–f and
Supplementary Tables 4 and 5).
To further assess how the presence of apo-sGC affects the
ability of NO to induce vasorelaxation, we performed vessel
reactivity studies on aortic rings isolated from WT and apo-sGC
mice. In accordance with the impaired cardiovascular effects of
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Figure 1 | Molecular characterization of apo-sGC mice. (a) Quantitative RT–PCR measurement of mRNA encoding sGC subunits in the brain (BR),
the kidney (KI), the lung (LU) and left ventricle (LV; n¼ 6 for all genotypes). (b) Representative and quantiﬁcation of sGC subunits in brain homogenates
of WT, HE and KI mice. *Po0.05, **Po0.01 and ***Po0.001 versus WT by one-way ANOVA (n¼4 for all genotypes). Data are mean±s.e.m. from
three independent experiments. (c) Aortic cGMP levels in untreated (WT: n¼ 12, HE: n¼ 11, KI: n¼ 11) and DETA-NO-treated mice (60mg kg 1;
WT: n¼ 7, HE: n¼ 7, KI: n¼ 7). ***Po0.001 versus baseline and ###Po0.001 versus WT by one-way ANOVA. (d,e) Basal (WT: n¼ 20, KI: n¼ 17),
DETA-NO-stimulated (WT: n¼ 20, KI: n¼ 17) and cinaciguat-stimulated (WT: n¼ 18, KI: n¼ 15) sGC enzyme activity in lung (d) and aortic (e) extracts of
WT and KI mice. ***Po0.001 versus baseline, #Po0.05 and ###Po0.001 versus WT by one-way ANOVA.
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NO in apo-sGC mice in vivo, acetylcholine, SNP, S-Nitroso-N-
acetylpenicillamine and NO gas-dependent relaxation were
abolished in apo-sGC aortic rings (Fig. 5a–d). Taken together,
these data demonstrate that NO-responsive sGC is required for
NO to induce vasorelaxation and lower BP.
Haemodynamic effects of sGC stimulators versus activators.
We then addressed whether loss of sGC haem affects the ability of
BAY 41-2272 to modulate BP and HR. In vivo administration of
BAY 41-2272 was associated with a BP decrease in WT mice but
not in apo-sGC mice (Fig. 4d, Supplementary Fig 4d, 6c,d and
Supplementary Tables 6 and 7). Similarly, the vasorelaxing
effect of BAY 41-2272 on WT isolated aortic rings was greatly
attenuated in aortic rings of apo-sGC mice (IC50E35 nmol l 1
and 1112 nmol l 1, respectively; Fig. 5e).
In contrast, in vivo administration of cinaciguat decreased BP
and increased HR in both apo-sGC mice and WT mice (Fig. 4e,
Supplementary Fig. 4e, 6e–f and Supplementary Tables 6 and 7).
In fact, the BP-lowering effect of cinaciguat in apo-sGC mice was
signiﬁcantly greater (Fig. 4e) and longer lasting (Supplementary
Fig. 7) than in WT mice. In addition, cinaciguat decreased BP in
apo-sGC mice at concentrations that did not affect BP in WT
mice (Supplementary Fig. 7). Furthermore, the IC50 values for
cinaciguat-induced ex vivo relaxation of precontracted aortas
were threefold lower in apo-sGC mice than in WT mice
(IC50E0.2 nmol l 1 and 0.7 nmol l 1, respectively; Fig. 5f).
Together, our results suggest that sGC activators like cinaciguat
but not sGC stimulators like BAY 41-2272 activate apo-sGC
in vivo. In addition, the observation that cinaciguat can modulate
vasorelaxation and BP in WT mice suggests that even in healthy
mice, a subset of the available sGC pool is haem-free and
responsive to sGC activators.
Reduced lifespan and altered morphology of apo-sGC mice.
Apo-sGC mice are viable but have a reduced lifespan, and display
gastrointestinal (GI) abnormalities and growth retardation. Other
strains of mice deﬁcient in key enzymes in the NO/sGC/cGMP
pathway have a shorter lifespan than WT mice20–22. Similarly,
we observed a reduced lifespan in apo-sGC mice compared with
WT and HE littermates (Fig. 6a). In addition, weight and size of
apo-sGC were consistently smaller than that of WT littermates
(Fig. 6b). Anatomical observation of apo-sGC mice revealed
reduced fat mass (Supplementary Fig. 8a–c), profound gastric
enlargement (Supplementary Fig 8a–c), signs of pyloric
constriction and an enlarged and translocated caecum
(Supplementary Fig. 8a). We assessed for malnutrition or lack
of appetite in apo-sGC mice by monitoring food intake
(Supplementary Fig. 9a), production of faeces (Supplementary
Fig. 9b) and serum levels of fructosamine, glucose and
triglycerides (measures of metabolic function). Intriguingly,
growth retardation in apo-sGC mice occurred despite a
signiﬁcantly increased food intake (Supplementary Fig. 9a).
Serum levels of fructosamine (Fig. 6e), but not glucose or
triglycerides (Fig. 6c,d), were lower in apo-sGC mice than in WT
mice. These results suggest that growth retardation in apo-sGC
mice is not due to malnutrition or malabsorption.
Apo-sGC mice are not protected against systemic TNF shock.
Administration of a dose of TNF, previously determined
to be lethal for WT mice, induced hypotension (Fig. 7a and
Supplementary Fig.10) and bradycardia (Fig. 7b) in both WT and
apo-sGC mice. During the ﬁrst 30min after TNF administration,
the decrease in BP was less pronounced in apo-sGC mice than in
WT mice (Fig. 7a and Supplementary Fig. 10, insert). The TNF-
induced mortality was similar in WT and apo-sGC mice in a
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Figure 2 | Characterization of WT and apo-sGC in CHO cells. (a) cGMP readout cells were co-transfected with WT-sGCa1 in combination with the WT
sGCb1-subunit or the mutant sGCb1H105F-subunit of sGC to generate WT- and apo-sGC, respectively. Baseline activity of WT-sGC (WT) and apo-sGC
(KI). **Po0.01; unpaired t-test. (b–e) Activation pattern of WT-sGC (b,c) and apo-sGC (d,e) incubated with increasing concentrations of cinaciguat alone
(’; b,d), increasing concentrations of cinaciguat in combination with a ﬁxed concentration of 10mM ODQ (&; b,d), increasing concentrations of BAY
41-2272 alone (m; c,e), or increasing concentrations of BAY 41-2272 in combination with a ﬁxed concentration of DEA/NO (n; c,e). Enzyme activity is
represented as relative light units (RLUs). Data are mean±s.e.m. from 5 to 7 independent experiments performed in quadruple, statistical analysis by
Student’s t-test.
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C57BL/6J background, and even increased in apo-sGC mice
in a 129S7 background (Fig. 7c,d). Together, these ﬁndings
demonstrate that NO-induced sGC activity is not required for the
cardiovascular collapse and lethality associated with TNF-
induced inﬂammatory shock.
Discussion
Oxidative stress, a major risk factor for cardiovascular disease1–3,
directly impairs sGC mediated signalling through oxidation of its
prosthetic haem group, resulting in the formation of haem-free
sGC or apo-sGC. Apo-sGC is insensitive to activation by NO
and susceptible to active degradation through the ubiquitin-
proteasome pathway23. sGC activators such as cinaciguat were
designed to speciﬁcally target and activate apo-sGC4,7,12 and
protect it from degradation23. As apo-sGC is a consequence of
oxidative stress, it is proposed that targeting apo-sGC and not
native sGC, may speciﬁcally target diseased organs without
having unwanted side effects because of ubiquitous sGC
activation. Maximizing the therapeutic potential of cinaciguat
and other haem-independent sGC activators requires a thorough
understanding of their target, apo-sGC, on a molecular and
physiological level, and of their mode of action both in vitro and
in vivo. However, investigations into the speciﬁc pathological
consequences of impaired sGC activity through haem-oxidation,
as well as the consequences of speciﬁcally activating the oxidized/
haem-free pool of sGC have been hampered by the incapacity to
distinguish native, haem-containing sGC from oxidized/haem-
free sGC in vivo7,8. We report the generation and cardiovascular
characterization of a viable line of apo-sGC mice, expressing a
NO-resistant sGC that can be activated by haem-independent
sGC activators, and identify novel aspects of the physiological role
of sGC and the in vivo actions of sGC activators.
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Figure 3 | Ablation of NO-inhibited platelet activation and hypertension in apo-sGC (KI) mice. (a) Tail bleeding time in WT and KI mice. ***Po0.001
versus WT by one-way ANOVA (WT: n¼ 29, HE: n¼ 30 and KI: n¼ 27). (b) Baseline (B), thrombin-induced (T) and NO-inhibited (TþNO) platelet
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thrombin and $Po0.05 versus WT thrombinþNO by two-way ANOVA (WT: n¼4, KI: n¼4). (c) Systolic blood pressure (SBP) measured using tail cuff in
conscious male and female WT, HE and KI mice. ***Po0.001 versus WT by one-way ANOVA (male WT: n¼42, HE: n¼ 25 and KI: n¼ 39; female WT:
n¼ 38, HE: n¼ 24 and KI: n¼ 36). Mean of 1000 hours to 1700 hours telemetric recordings for SBP (d) and heart rate (HR) (e) in KI and WTmice.
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The observation that protein levels of sGC subunits are lower
in tissues from apo-sGC than in WT mice conﬁrms recent in vitro
and ex vivo ﬁndings suggesting that the ferrous haem group
protects sGC from degradation9,23. Nonetheless, the ﬁnding that
apo-sGC can exist in vivo illustrates that targeting oxidized sGC
represents a feasible therapeutic approach in cardiovascular (and
other) disorders characterized by increased oxidative stress and
subsequent oxidation of sGC.
Tissue cGMP levels and sGC catalytic activity in tissue
homogenates were similar in WT, HE and apo-sGC mice. When
taking into account the lower sGC protein levels in apo-sGC mice
than in WT mice, these results suggest that apo-sGC has a higher
basal activity than the WT enzyme. Using a cGMP-reporter
cell line, we conﬁrmed the higher basal activity of overexpressed
apo-sGC in vitro. These results support previously reported
ﬁndings that basal activity of a haem-free mutant of sGC or of
detergent-treated haem-free sGC that lacks the characteristic
Soret peak at 431 nm is higher than that of WT sGC24,9.
Together, these ﬁndings suggest that the ligand-bound
haem-group acts as an endogenous inhibitor of sGC25.
The lifespan of apo-sGC mice is shorter than that of WT mice
but similar to that described for mice deﬁcient in all three NOS
isoforms22. These data suggest that NO affects longevity in an
sGC-dependent manner. Importantly, the lifespan of apo-sGC
mice, with more than 90% survival at 31 days, is substantially
longer than that of sGCb1 / mice, with less than 10% of
sGCb1 / offspring surviving longer than 31 days20. The
difference in survival between apo-sGC mice and sGCb1 /
mice suggests a pivotal role for NO-independent sGC activity in
determining survival and longevity in mice.
NO-sGC-cGMP signalling was previously demonstrated to be
an important mediator in the relaxation of the stomach in
reﬂex to increases in gastric pressure26. Similar to observations
made in NOS1 / and cGMP-dependent protein kinase 1 /
(PKGI / ) mice21,27,28, gastric enlargement, signs of pyloric
constriction and a delayed GI transit time were present in
apo-sGC mice29. The gastric enlargement in apo-sGC is therefore
likely caused by pyloric constriction and delayed gastric
emptying29. Comparable to sGCb1 / mice20, an enlarged
and translocated caecum was observed in apo-sGC mice.
Together, these data conﬁrm that activation of sGC by NO is
necessary for normal GI function and that basal levels of cGMP
produced by apo-sGC are not sufﬁcient to fully preserve GI
function and morphology. However, basal cGMP production in
apo-sGC mice seems sufﬁcient to prevent the fatal GI dysfunction
observed in sGCb1 / mice20. It is conceivable that the
observed growth retardation is secondary to abnormal GI
function. However, normal triglyceride and glucose levels
suggest that impaired GI function in apo-sGC mice does not
result in malnutrition. It remains to be determined whether
alterations in metabolism or tissue development contribute to the
reduced fat mass observed in apo-sGC mice despite an increase in
food uptake.
The ability of NO to inhibit platelet activation30, to induce
vascular smooth muscle relaxation and to lower BP is well
characterized31. Consistent with results in sGCb1 / ,
sGCa1 / and PKGI / mice20,32–34, lack of NO-dependent
sGC activation completely abrogated the anti-platelet and
BP-lowering effects of NO. These results demonstrate that
haem-containing, reduced sGC is required for NO’s effects on
platelets and systemic vasorelaxation.
sGC stimulators are a novel class of molecules that stimulate
the catalytic activity of sGC, and that have been successfully
developed for therapeutic use in PAH13. They are dependent on
interaction with the sGC haem-group to activate the enzyme, and
can activate sGC in a synergistic manner with NO35. The ability
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of BAY 41-2272 to activate apo-sGC, either alone or in synergy
with NO, or to relax aortic rings was severely attenuated.
The residual effect of BAY 41-2272 in aortic rings of apo-sGC
mice is likely due to off target effects, including its inhibitory
effect on phosphodiesterases at concentrations higher than
5 mmol l 1 (refs 35,36). Similarly, administration of BAY
41-2272 decreased BP in WT but not apo-sGC mice. These
results conﬁrm the absence of haem in the apo-sGC enzyme and
demonstrate that apo-sGC cannot be activated by BAY 41-2272
in vivo.
Cinaciguat, a member of a new class of haem-independent sGC
activators, exclusively activates haem-free sGC by binding in the
haem pocket and changing the enzyme’s conformation14. In a
cGMP reporter cell line transfected with WT sGC, ODQ, a
known oxidizer and inhibitor of sGC, potentiated the ability of
cinaciguat to activate sGC. In contrast, ODQ did not affect the
activation proﬁle of cinaciguat in a cGMP reporter cell line
transfected with apo-sGC, indicating again that apo-sGC is
completely haem-free. It is noteworthy that, despite lower sGC
protein levels in tissues isolated from apo-sGC mice than WT
mice, IC50 values for cinaciguat-induced ex vivo relaxation of
precontracted apo-sGC aortas were lower than those in WT
aortas. In addition, cinaciguat had a more potent effect on BP in
apo-sGC mice than in WT mice. Our ex vivo aortic ring
experiments and in vivo BP observations validate the hypothesis
that cinaciguat can activate haem-free/oxidized sGC in relevant
tissues.
The observation that cinaciguat also has effects on sGC
activation, vasorelaxation and BP in WT cellular systems, WT
organ baths and WT mice, respectively, is an indication that in
normal circumstances, a subset of the available pool of sGC is
haem-free. Consequently, sGC activators may also impact healthy
tissue. Whether this is due to the presence of low levels of
oxidative stress in healthy organisms or whether the interaction
of the haem group with sGC is dynamic in vivo remains
unresolved. In the latter case, at higher concentrations, cinaciguat
might be able to compete with the haem group for binding to
sGC as was suggested previously8. When attempting to estimate
the amount of apo-sGC in healthy tissues, it should be stressed
that the correlation between sGC activity, the amount of cGMP
produced and the resulting physiological response is weak. For
example, in sGCa1 / mice, the sGCa2b1 isoform, expressed at
20-fold lower levels than sGCa1b1 in vascular tissue, was
sufﬁcient to mediate a robust vasorelaxing response and BP
lowering effect of NO, in the absence of a measurable increase in
cGMP content32,33. More importantly, by titrating the dose
of cinaciguat in vivo, we were able to observe a reasonable
therapeutic window in which beneﬁcial properties of reactivation
of haem-oxidized sGC might be achieved, while avoiding
unwanted systemic side effects. Our observations imply that
careful dosing and titration might be necessary in developing
therapeutic approaches to attain speciﬁcity for diseased organs.
Together, these results demonstrate the validity of the concept
that loss of the haem of sGC in vivo, suggested to occur during
conditions of increased oxidative stress4, results in elevated
systemic BP that can be decreased by sGC activators such as
cinaciguat. sGC presents advantages as a therapeutic target for
pathologies associated with oxidative stress for two reasons. First,
it is downstream from NOS enzymes, which were shown to exert
other functions besides sGC activation and which produce free
radicals themselves under conditions of oxidative stress. Second,
sGC is a target of oxidative damage and can be reactivated by
haem-independent sGC activators like cinaciguat. The apo-sGC
mouse model provides a unique experimental platform to directly
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study both the effects of the increased presence of oxidized or
haem-free sGC, and the therapeutic ability of sGC activators.
Mortality associated with systemic inﬂammatory response
syndromes (SIRS), such as the cytokine storm syndrome and
sepsis, is the highest in the subset of patients who develop shock.
The pathophysiology of the ﬁrst stages of SIRS, including
infection, and immune and inﬂammatory reactions, is quite
heterogeneous, with mechanisms ranging from immune paralysis
to cytokine storm37. However, the development of the
cardiovascular collapse in SIRS has generally been considered to
depend on a few common mechanisms, of which NO-sGC-cGMP
signalling is a major culprit in vasodilation, distributive shock and
cardiodepression17,18. In both animal models and patients, NO
produced by inducible NOS2 was implicated in both vasodilation
and cardiodepression during shock. Unfortunately, in subsequent
clinical trials, inhibition of NOS was found to increase BP in
sepsis patients but failed to improve survival. In fact, treatment
with non-isoform-speciﬁc NOS inhibitors was associated with
higher mortality38. Further research identiﬁed the existence of
NOS-dependent protective cardiovascular effects in SIRS. We
previously reported that mice deﬁcient in sGCa1 (sGCa1 /
mice) are sensitized to the cardiac dysfunction and mortality
associated with inﬂammatory shock (both endotoxin-induced and
TNF-induced shock), suggesting that sGCa1b1-derived cGMP is
cardioprotective in murine inﬂammatory shock models. In
addition, we have recently shown that the haem- and NO-
independent sGC activator BAY 58-2667 (Cinaciguat), can improve
organ function and survival during lethal endotoxemia when given
in the appropriate treatment window39. Together, these
considerations frame the ongoing debate on the exact role, be it
detrimental40–44 or protective45–48, of NO-sGC-cGMP signalling in
the cardiovascular collapse during shock.
The availability of NO-insensitive apo-sGC mice facilitates
research into testing the hypothesis whether the cardiovascular
collapse in SIRS depends on NO-dependent sGC activation.
To do so, we opted for a TNF-induced SIRS model characterized
by a marked increase in systemic NO levels, in which the
cardiovascular collapse is a most prominent feature, and which
mimics the human situation in its cardiovascular aspects49–51.
Using a downstream effector as a challenge instead of an
infectious challenge avoids as much as possible that the observed
consequences of modulation of the NO-sGC-cGMP pathway
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would be due to interference with the effects of this pathway on
infection control and on the regulation of the generation of an
immune and inﬂammatory response itself, rather than on
the effects of NO-sGC-cGMP on the cardiovascular system.
Indeed, NO-sGC-cGMP signalling has also effects outside the
cardiovascular system, such as in infection control and in the
regulation of the generation of an immune and inﬂammatory
response. Administration of a lethal dose of TNF induced similar
hypotension and bradycardia in WT and apo-sGC mice. Only in
the ﬁrst 30min after TNF administration, a time at which NO is
derived from NOS3 rather than NOS2, the decrease in BP was
more pronounced in WT than in apo-sGC mice. This suggests
that the early, NOS3-derived effect of TNF on BP is mediated in
part by the sGC/cGMP pathway, whereas the later effects are sGC
independent. The TNF-induced mortality was similar in WT and
apo-sGC mice on a C57BL/6J background, and even higher in
apo-sGC mice than in WT mice on a 129S7 background. Even
though a poor nutritional status has been associated with
increased mortality in inﬂammatory shock52, it is unlikely that
malnutrition contributes to the increased mortality in apo-sGC
mice taking in to account the normal triglyceride and glucose
levels of apo-sGC mice. These results indicate that NO-sGC-
dependent signalling is not required for cardiovascular collapse or
for mortality associated with inﬂammatory shock. Together with
recent observations that excessive production of systemic NOS2-
derived NO is not necessarily associated with haemodynamic
collapse53, our observations in apo-sGC mice challenge the
prevailing paradigm of the central and crucial role of NO/sGC
signalling in inﬂammatory shock. An alternative mechanism
leading to septic shock might be the direct oxidative activation of
PKG1 as proposed recently2. These observations do not exclude
protective or deleterious involvement of NO-sGC-dependent
signalling in the antimicrobial or inﬂammatory aspects of the
pathophysiology of sepsis but only imply that NO-sGC signalling
is not the pathway resulting in cardiovascular collapse.
In conclusion, this paper describes the cardiovascular pheno-
type of a novel mouse model that allows us to distinguish between
sGC-dependent and sGC-independent effects of NO and between
haem-dependent and haem-independent effects of sGC. Our
results highlight the importance of sGC as the primary receptor
for NO in cardiovascular physiology, and identify an important
role for haem-independent activity of sGC in determining
survival and longevity. In addition, we demonstrated that, in a
model of TNF-induced systemic shock, NO/sGC/cGMP signal-
ling is not responsible for the prolonged refractory hypotension
or for mortality. The data presented here illustrate the therapeutic
potential of compounds able to activate apo-sGC in setting
of cardiovascular disease, including systemic hypertension,
providing a solid scientiﬁc ground for the further development
of this new class of drugs.
Methods
Generation of apo-sGC mice. The sGCb1-targeting vector was constructed using
a 10.5-kb genomic DNA contig picked up by screening of a 129SvJ lambda FIX II
mouse genomic library (Stratagene). A targeting vector containing a 3-kb 30 and a
4.1-kb 50 ﬂanking homology, a positive, loxP ﬂanked (neomycin-resistance cassette,
Neor) and a negative (thymidine kinase cassette, TK) selection marker was
constructed, in which the histidine residue at position 105, located in exon 5,
was mutated to phenylalanine (Supplementary Fig. 1). Five other silent mutations
were introduced as well. The mutations were introduced using the Transformer
Site-Directed Mutagenesis Kit (Clontech Laboratories, Inc.). Targeting was applied
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in a 129SvEv mouse embryonic stem cell line54 and 263 G418-resistant clones were
selected from the respective lines. Correct homologous recombination was
conﬁrmed through Southern blot (Supplementary Fig. 1b, c) and multiple
integration events were ruled out by PCR (Supplementary Fig. 1d). One positive
clone was expanded and subjected to Cre-mediated deletion of the neomycine
cassette by transient transfection with the Cre-expression plasmid pCAGGS-Cre.
G418-sensitive clones were selected and screened for successful deletion of the neo
cassette through Southern blot (Supplementary Fig. 1b, c) and PCR
(Supplementary Fig. 1d). In vitro Cre-Lox-mediated deletion of the Neor-cassette
after transfection of 129SvEv embryonic stem cells was veriﬁed by Southern blot
using probes located at the 50 and 30 end of the construct, and by PCR (primers:
P1F: 50-GACCCACAGCCCAAGTGTAAC-30 ; P1R: 50-GAAGAGCTTGGCGGC
GAATG-30) spanning the entire 3 kb homology arm. Chimeras were generated by
blastocyst injection of C57Bl/6J blastocyst-stage embryos with a correctly targeted
ES cell clone54 and implantation in a pseudo-pregnant female. Germline
transmission was veriﬁed by mating male chimeras to C57Bl/6J females.
Subsequent generation of apo-sGC mice by mating male and female mice HE for
the mutated allele, was conﬁrmed by Southern blot and RT–PCR (Supplementary
Fig. 1e; primers: P2F: 50-GAACATTAAATTAGCCG-30 ; P2R: 50-GTTATCAATA
GCu8ATCAGG-30).
Animals. Mice were bred and maintained in speciﬁc pathogen-free conditions in
the animal facility of IRC/VIB1, Ghent. Mice were housed in temperature- and
humidity-controlled conditions at 21 C and 40–65% relative humidity, 14 h/10 h
light/darkness, with ad libitum food and water. Mice were fed irradiated ‘Trans-
breed’ chow (SDS), unless stated otherwise, and regular drinking water. The genetic
background of the mice is an F2 mixed background of 129SvEv x C57Bl/6J, except
if stated otherwise. In all experiments, equal numbers of male and female mice
between 12 and 18 weeks were used, unless stated otherwise. In all experiments,
littermates were used as controls. All experiments were conform to the Belgian and
European law on laboratory animal experimentation and were approved by the
Local Ethical Committee of Ghent University.
Growth curve. Apo-sGC mice were fed three different rodent chows: standard
pellets (SNIFF), expanded diets (RM3, SDS) and a high-energy and high-nutrient
diet (Transbreed, SDS). Body weights were measured from 3 to 15 weeks of age.
As no statistical interaction was observed between growth curves on different diets,
all curves were combined in one ﬁnal growth curve.
Metabolic cages. Mice were placed individually in metabolic cages (Techniplast)
with food and water ad libitum, and allowed to adapt for 3 days. Starting from
day 4, 24 h faeces were collected and 24 h food uptake was measured for 3 con-
secutive days.
Collection and analysis of blood. Mice were fasted for 16 h, anaesthetized with
isoﬂurane and blood was collected by cardiac puncture and kept for 30min at room
temperature to promote clot formation. Serum was prepared by cold centrifugation
at 3000g for 20min. Serum was stored at  20C until use. Serum glucose was
determined using routine methods using commercial reagents (Roche) on a Cobas
6000 analyzer (Roche). Fructosamine levels were determined on a Cobas-Mira
Chemistry Analyzer using the Roche reagents (Roche). Triglyceride levels were
determined with the EnzyChrom Triglyceride Assay Kit (BioAssay Systems)
according to the manufacturer’s instructions.
Harvesting of organs. Mice were killed by cervical dislocation and organs were
quickly dissected and weighed or snap frozen for immunoblot, sGC activity, cGMP
concentration and RT Q–PCR, and stored at  70 C.
Immunoblot analysis and quantiﬁcation of sGC subunits. Tissue samples were
pulverized at  70 C (Retsch MM301), homogenized in 1ml ice-cold lysis-buffer
(HEPES 20mmol l 1, NaCl 350mmol l 1, Triton X-100 0.5%, EDTA
0.5mmol l 1, Glycerol 20%) supplemented with 1 mmol l 1Pefabloc SC (Roche
Diagnostics), 0.3 mmol l 1 Aprotinin (Roche Diagnostics), 1 mmol l 1 Leupeptin
(Roche Diagnostics), 25mmol l 1 b-glycerolphosphate, 1mmol l 1 NaOVO3,
5mmol l 1 NaF and ‘complete’ EDTA-free protease inhibitor cocktail (Roche),
using a mechanical homogenizer (Polytron PT1600E) for protein extraction.
Samples were centrifuged at 14,000g for 20min at 4 C. Protein extracts (brain
100mg, lung 100 mg) were separated on a 10% SDS–polyacrylamide gel and
transferred to nitrocellulose ﬁlters. sGCa1 and sGCb1 were detected using a rabbit
anti-rat antibody from Sigma (G4280 and G4405, respectively, 1:500), and for
sGCa2, a rabbit anti-human antibody from Abcam (ab42108 1:500) was used.
Immunoblotting with monoclonal mouse anti-human actin (MP Biomedicals,
1:2000) was performed to correct for equal loading. Detection and analysis were
performed with the Odyssey system (Odyssey 2.1.12, Li-Cor Biosciences) using
ﬂuorophore-coupled secondary antibodies (goat anti-mouse IRDye 680, goat
anti-rabbit IRDye 800CW, Li-Cor Biosciences, all at 1:5,000). Results were
normalized to actin and expressed as a percentage of WT.
sGC enzyme activity. To measure sGC enzyme activity, lung, aorta, brain and
left ventricle tissues were harvested and homogenized in buffer containing
50mmol l 1 Tris-HCl (pH 7.6), 1mmol l 1 EDTA, 1mmol l 1 dithiothreitol and
2mmol l 1 phenylmethyl sulphonyl ﬂuoride. Extracts were centrifuged at 20,000g
for 20min at 4 C. Supernatants (containing 50 mg protein) were incubated for
10min at 37 C in a reaction mixture containing 50mmol l 1 Tris-HCl (pH 7.5),
4mmol l 1 MgCl2, 0.5mmol l 1 1-methyl-3-isobutylxanthine, 7.5mmol l 1
creatine phosphate, 0.2mgml 1 creatine phophokinase, 1mmol l 1 L-NAME
and 1mmol l 1 GTP with or without 10mmol l 1 DETA-NO, 100mmol l 1
cinaciguat or 1mmol l 1 Bay 41-2272. The reaction was terminated by adding
0.9ml of 0.05mol l 1 HCl. cGMP was measured using a commercial radio-
immunoassay (Biomedical Technologies). sGC enzyme activity is expressed as
picomoles of cGMP produced per minute per milligram of protein in extract
supernatant.
cGMP concentrations. Mice were dissected immediately or 10min after intra-
peritoneally (IP) injection of 60mg kg 1 DETA-NO. Harvested organs were ﬁrst
powdered at  70 C (Retsch MM301) and subsequently homogenized in 1ml
ice-cold 100% ethanol. Extracts were centrifuged at 14,000g for 10min at 37 C.
The supernatant was transferred and the pellet was washed once with 0.5ml
ice-cold 100% ethanol and centrifuged at 14,000g for 10min at 37 C. The total
supernatant was dried under vacuum at 30 C. The pellet was redissolved in protein
buffer (20mmol l 1 HEPES, 350mmol l 1 NaCl, 0.5mmol l 1 EDTA, 20%
glycerol, 0.5% Triton X-100, EDTA-free protease inhibitor mix), centrifuged for
10min at 14,000g at 37 C and protein concentration of the supernatant was
measured using a BCA Protein Assay Kit (Pierce). cGMP pellets were dissolved
in EIA-buffer and cGMP concentrations were measured using the acetylation-
protocol, of the Cyclic GMP EIA Kit (Cayman Chemical). cGMP concentration
is expressed as picomole cGMP per milligram of protein.
Measurement of mRNA expression levels. Tissues were harvested, rinsed in
PBS, snap frozen in liquid N2 and stored at  70 C until RNA was extracted using
the RNeasy Plus Protect Mini kit from QIAGEN according to the manufacturer’s
instructions. One microgram of RNA was used in the iScript cDNA Synthesis Kit
(Bio-Rad) for RT–PCR to produce cDNA using random hexameric primers. cDNA
was subsequently used for relative expression quantiﬁcation using the LightCycler
480 SYBR Green I Master mix (Roche Diagnostics) in a Lightcycler 480 (Roche).
To this end, subunit-speciﬁc primer sets were synthesized (see Supplementary
Table 1). To normalize the data, the geometric mean of the two most stable
housekeeping genes, 60S ribosomal protein L13 (RPL13) and b-actin (ACTB), out
of ﬁve tested genes, calculated with the geNorm Housekeeping Gene Selection
Kit (PrimerDesign Ltd) was used55. Each sample was measured in triplicate to
determine the threshold cycle (Ct). For each sample, the normalization factor was
calculated as the difference between the geometric mean Ct of the housekeeping
genes of the sample and the mean Ct of the housekeeping genes of all samples. The
level of target mRNA, relative to the mean of the reference housekeeping genes, was
calculated by raising 2 to the power of [40 - (Ct of target - housekeeping gene
normalization factor)]. Data±s.e. are plotted as relative amount versus WT
male¼ 100%.
Characterization of WT and apo-sGC in a CHO reporter cell line. Mutagenesis
of a plasmid expressing WT sGCb1 was performed using the QuikChange site-
directed mutagenesis kit according to the manufacturer’s protocol. The following
primer was used to perform the desired mutation: b1H105F:50-CGATGCCCTG
TTCGACCACCTCG-30 . The accuracy of the mutation was veriﬁed by sequencing
(Invitek).
To characterize the sGC mutant in an intracellular environment, a cGMP
reporter cell was constructed based on a method reported earlier56. Brieﬂy, a CHO
cell line expressing cytosolic aequorin was stably transfected with a plasmid coding
for the cGMP-gated ion channel CNG2 under a zeocin resistance. Thereafter,
zeocin-resistant clones were characterized for a channel expression, and active
clones were subcloned by the limited dilution technique. Selected clones were
cultured in Dulbecco’s modiﬁed Eagle’s medium pyruvate /F12 with L-glutamine
(Invitrogen), 1 nmol l 1 sodium pyruvate and 50 mgml 1 streptomycin,
2.5 mgml 1 amphotericin B and 10% (v/v) inactivated fetal calf serum.
For cGMP readout cells were seeded on 96-well microtitre plates at a density of
10,000 cells per well and were cultured for 1 day at 37 C and 5% CO2 to ensure
conﬂuent growth. Afterward, cells were co-transfected applying a transfection
mixture containing 9 ng of a1- and 9 ng of b1-plasmid, 0.12 ml of Plus reagent and
0.75 ml of LipofectAMINE (Invitrogen) in 100 ml OptiMEM serum-free medium
(Invitrogen) according to the manufacturer’s protocol. After 3 h at 37 C, the
transfection medium was replaced with serum-containing medium and cells were
incubated for 24 h at 37 C to ensure optimal expression of WT- and mutant-sGC.
Cells were cultured and transiently transfected with WT-sGC or mutant-sGC as
described above. 24 h after transfection medium was removed, and the transfected
cells were incubated with calcium-free buffer ((130 nmol l 1 NaCl, 5mmol l 1 KCl,
20mmol l 1 HEPES, 1 nmol l 1 MgCl2, 4.8nmol l 1 NaHCO3, pH 7,4) containing
0.83mgml 1 coelenterazine for 3 h at 37 C. For the determination of the sGC
activation proﬁle, cells were incubated with various concentrations of sGC activator,
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cinaciguat or sGC stimulator, BAY 41-2272 or in the presence of 10mmol l 1 ODQ
or 1 nmol l 1 DEA/NO in a volume of 50ml for 10min at RT. 3-Isobutyl-1-
methylxanthin was used in a ﬁnal concentration of 66.7mM to prevent cGMP
degradation by endogenous PDEs. cGMP readout was initiated by application of
buffer containing 10mmol l 1 CaCl2 and emitted light was measured as relative
light units in a light-tight box using charge-coupled device camera.
Platelet activation. To isolate platelets, 400 ml blood was collected in 100 ml Acid
Citrate Dextrose buffer (16.77 g l 1 tri-sodium citrate dihydrate; 14 g l 1, citric
acid; 18.016 g l 1, dextrose; pH 6.5) and diluted in 500ml PIPES-buffered saline.
Platelet-rich plasma was prepared by centrifugation of samples at 100g for 20min.
To prepare platelets, the supernatant of the platelet-rich plasma was added to
500ml of platelet wash buffer (140mmol l 1 NaCl; 10mmol l 1 NaHCO3;
2.5mmol l 1 KCl; 0.5mmol l 1 Na2HPO4; 1mmol l 1 MgCl2; 6.46mmol l 1
tri-sodium citrate dihydrate; 0.1% dextrose; 0.35% bovine serum albumin; pH 6.5)
containing 3Uml 1 Apyrase. Platelets were pelleted by centrifugation at RT
at 500g for 15min, and resuspended in 400ml of sterile Tyrode’s HEPES
(134mmol l 1 NaCl; 12mmol l 1 NaHCO3; 2.9mmol l 1 KCl; 0.34mmol l 1
Na2HPO4; 1mmol l 1 MgCl2; 1mmol l 1 CaCl2; 10mmol l 1 HEPES; 0.9%
dextrose; 0.35% bovine serum albumin; pH 7.4; 1.125mmol l 1 Gly-Pro-Arg-Pro).
Platelets were incubated with CD62P-FITC antibody (BD Pharmingen 1:500) in
the presence of SNP (36 mmol l 1) or not, and subsequently activated with murine
a thrombin (0.01Uml 1) during 15min. Surface expression of CD62P on
platelets was analysed by mean ﬂuorescence of platelet populations between
conditions using a FACScalibur (BD Biosciences) ﬂow cytometer57.
Blood clotting. Male and female mice (12 weeks old) were anaesthetized with
isoﬂurane, 0.5 cm of the tail tip was removed with a sharp razor blade, and the tail
tip was immediately put into fresh pre-warmed PBS of 37 C. The latency until the
tail stopped bleeding was visually scored and recorded with a chronometer by an
observer blinded to the genotype.
Telemetric BP measurements. BP measurements in conscious, freely moving
mice were made using implantable, miniaturized mouse BP transmitters (model
PhysioTel PA-C10, Data Science International)58. Brieﬂy, mice weighing at least
20 g were anaesthetized with isoﬂurane, the left carotid artery was made accessible,
and a catheter tip was inserted into the artery just before the entry of the aortic
branch. The telemetric device was placed under the abdominal skin. After surgery,
the mice were allowed to recover for 7 days before starting the measurements.
Radiofrequency signals from the transmitters were converted to serial bit streams
and data were collected and stored to disk using the Dataquest A.R.T. data
acquisition system (Data Sciences International). Ambient barometric pressure was
also measured and subtracted from the telemeter pressure by the Dataquest A.R.T.
software to compensate for changes in atmospheric pressure58. Transducer
sampling frequency was at 1,000Hz and measurements were acquired in a
continuous matter over 24 h. L-NAME (100mg kg 1), SNP (1.5mg kg 1),
DETA-NO (60mg kg 1), cinaciguat (300 mg kg 1) and the vehicle controls
(PBS or for cinaciguat 20% Cremophor (Fluka)þ 20% diethylene-glycol-
monoethyl-ether (Sigma) in PBS) were all administered intravenously (IV).
BAY 41-2772 (4mg kg 1) and vehicle control (20% Cremophor (Fluka)þ 20%
propylene glycol monomethyl ether (PGME (Sigma) in PBS)) were administered
IP. Murine TNF (480 mg kg 1) was administered IV. For 24-h BP and HR,
averages of 1 h intervals were used for statistical analysis. For SNP measurements,
averages of 1-min intervals of continuous data acquired at 1–15min post injection
were used for statistical analysis. For mTNF measurements, averages of 5-min
intervals of continuous data acquired 1–8 h post injection were used for statistical
analysis. For measurement of all other administrations, averages of 1-min intervals
of continuous data acquired at 1–25min post injection were used for statistical
analysis.
Non-invasive BP measurements. SBP and HR were measured non-invasively in
awake mice by tail-cuff using a Hatteras MC4000 Blood Pressure Analysis System
(model MC4000MSP, Hatteras Instruments, Inc.)59. Mice were habituated to the
BP measurement device for 7 days. To determine basal BP, mice were measured for
15 consecutive cycles per day during 5 days. L-NAME (100mg kg 1), SNP
(1.5mg kg 1), DETA-NO (60mg kg 1), BAY 41-2772 (4mg kg 1), cinaciguat
(30 mg kg 1) and the vehicle controls (PBS or for the BAY-compounds 20%
Cremophor (Fluka)þ 20% diethylene-glycol-monoethyl-ether (Sigma) in PBS)
were all administered IP. After SNP administration, SBP measurements were
recorded from 5 to 15min post injection, for L-NAME and DETA-NO recordings
were made from 1 to 25min post injection and for BAY-compounds recordings
were made from 10 to 25min post injection.
Aortic rings. The thoracic aorta from apo-sGC mice and WT littermates of both
genders were studied in parallel. For isometric tension recording, ring segments
(2mm length) were mounted in a Mulvany–Halpern myograph organ bath con-
taining physiological Krebs–Ringer bicarbonate solution at 37 C gassed with 95%
O2/5% CO2. Following a 30-min equilibration, the aortic rings were gradually
stretched to a stable preload of 0.5 g and treated three times with 120mmol l 1
Kþ and 0.06 nmol l 1 phenylephrine. As soon as a stable contraction was
obtained, the effects of cumulative additions of Ach (1 nmol l 1–10 mmol l 1),
SNP (1 nmol l 1–10 mmol l 1), S-nitroso-N-acetylpenicillamine (1 nmol l 1–
10 mmol l 1), NO gas (10 nmol l 1–0.1mmol l 1), BAY 41-2272 (1 nmol l 1–
1 mmol l 1, Alexis Biochemicals) and BAY 58-2667 (1 nmol l 1–1 mmol l 1)
were recorded.
Statistical analysis. All data are shown as mean±s.e. For pairwise analysis,
Student’s t-tests were used. Multiple-group comparisons were made using one- or
two-way analysis of variance (ANOVA), as appropriate (see Supplementary Table 2
for respective experiment, number of samples and statistics used). Multiple
comparison was performed after obtaining a signiﬁcant ANOVA F-test. Multiple
testing correction was done using the Bonferroni method. IC50 values were
calculated using a nonlinear regression curve ﬁtting model with variable slope.
Student’s t-tests, one- and two-way ANOVA were performed using 6.0 f for Mac
(GraphPad Software, http://www.graphpad.com).
Repeated measurements data were analysed by ﬁtting the following linear mixed
model: yijkl¼ mþ giþ cjþ tkþ gcijþ gtikþ ctjkþ gctijkþ eijkl, where yijkl is the
phenotypic value of the lth individual; m is the mean term; gi is the effect of the ith
genotype (i¼ 1y2;WT and KI for telemetric data and i¼ 1y3; WT, HE and KI
for tail-cuff data); cj is the effect of the jth treatment (j¼ 1y2; compound and
control); tk is the effect of the kth time point and eijkl is the residual effect, eijkl
BN(0, se2) with se2 being the residual variance. Times of measurements were
equally spaced and various ways of modelling the correlation structure (uniform,
autoregressive order 1 (AR1) or 2 (AR2), and antedependence order 1 and 2) were
compared in the residual maximum likelihood (REML) framework as implemented
in Genstat60. Selection of the best model ﬁt was based on a likelihood ratio test
statistic and the Aikake Information coefﬁcient. When residuals from the analysis
indicated increasing variance over time, this was modelled directly by specifying
that heterogeneity is to be introduced into model. Signiﬁcance of the ﬁxed main
and interaction effects was assessed by either a Wald test or a F test.
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